ATE384125T1 - Antikörper gegen cd-80 - Google Patents

Antikörper gegen cd-80

Info

Publication number
ATE384125T1
ATE384125T1 AT96922439T AT96922439T ATE384125T1 AT E384125 T1 ATE384125 T1 AT E384125T1 AT 96922439 T AT96922439 T AT 96922439T AT 96922439 T AT96922439 T AT 96922439T AT E384125 T1 ATE384125 T1 AT E384125T1
Authority
AT
Austria
Prior art keywords
antibodies against
antibodies
Prior art date
Application number
AT96922439T
Other languages
English (en)
Inventor
Darrell Anderson
Peter Brams
Nabil Hanna
William Shestowsky
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE384125T1 publication Critical patent/ATE384125T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96922439T 1995-06-07 1996-06-06 Antikörper gegen cd-80 ATE384125T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/487,550 US6113898A (en) 1995-06-07 1995-06-07 Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies

Publications (1)

Publication Number Publication Date
ATE384125T1 true ATE384125T1 (de) 2008-02-15

Family

ID=23936199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96922439T ATE384125T1 (de) 1995-06-07 1996-06-06 Antikörper gegen cd-80

Country Status (24)

Country Link
US (4) US6113898A (de)
EP (2) EP1914301A1 (de)
JP (1) JP4242451B2 (de)
KR (1) KR100496307B1 (de)
CN (2) CN101367877A (de)
AR (2) AR001288A1 (de)
AT (1) ATE384125T1 (de)
AU (1) AU707023B2 (de)
BR (1) BR9609035A (de)
CA (1) CA2223532C (de)
CO (1) CO4480111A1 (de)
DE (1) DE69637408T2 (de)
DK (1) DK0837927T3 (de)
ES (1) ES2301169T3 (de)
IL (1) IL122370A (de)
MY (1) MY136224A (de)
NO (1) NO328554B1 (de)
NZ (1) NZ311904A (de)
PT (1) PT837927E (de)
SA (1) SA96170473B1 (de)
UY (1) UY24256A1 (de)
WO (1) WO1996040878A1 (de)
YU (1) YU35996A (de)
ZA (1) ZA964547B (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
PT892643E (pt) * 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
EP1878748A2 (de) * 1996-11-08 2008-01-16 Biogen Idec Inc. Identifikation der Wechselwirkungen einzelner Bindungen zwischen gewissen Antikörpern und humanen kostimulierenden B7.1- und B7.2-Antigenen
EP0988321A2 (de) * 1997-06-20 2000-03-29 Innogenetics N.V. B7-bindungsmolekülen zur behandlung von immunkrankheiten
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
HK1043312B (en) 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
HUP0202238A3 (en) * 1999-07-12 2004-05-28 Idec Pharmaceuticals Inc San D Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
SE9903895D0 (sv) * 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20010055593A1 (en) * 2000-03-14 2001-12-27 Joseph Sypek Use of rapamycin and agents that inhibit B7 activity in immunomodulation
KR20020091170A (ko) 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
US6379900B1 (en) 2000-05-09 2002-04-30 Conceptual Mindworks, Inc. Compositions and methods of use of 8-nitroguanine
KR20030007899A (ko) * 2000-06-09 2003-01-23 브리스톨-마이어스스퀴브컴파니 림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법
EP1299128A2 (de) 2000-06-20 2003-04-09 Idec Pharmaceuticals Corporation Kaltes anti-cd20 antikörper/radiomarkiertes anti-cd22 antikörper kombination
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HRP20030071B1 (hr) 2000-07-03 2014-01-03 Bristol-Myers Squibb Company Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
CA2436139A1 (en) * 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US6955717B2 (en) * 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
MXPA03010568A (es) * 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
IL161988A0 (en) 2001-11-16 2005-11-20 Corporation Idec Pharmaceutica Polycistronic expression of antibodies
AR038605A1 (es) 2002-02-25 2005-01-19 Elan Pharm Inc Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
DK1599173T3 (en) * 2002-11-13 2017-06-06 Uab Res Found SYNTHETIC SINGLE DOMAIN POLYPEPTIDES SIMILARING APOLIPOPROTEIN E AND PROCEDURES FOR THEIR USE
AU2004264901B2 (en) * 2003-08-04 2009-12-10 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble CTLA4 molecule
JP4745972B2 (ja) * 2003-10-21 2011-08-10 メルク セローノ ソシエテ アノニム クロマチンインスレーターとして作用する極小ｄｎａ配列、及びタンパク質発現におけるその使用
US20070212301A1 (en) * 2003-11-07 2007-09-13 Amgen, Inc. Monkey Immunoglobulin Sequences
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN100369931C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人b7-1分子单克隆抗体及其应用
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
HRP20150512T1 (hr) 2007-09-04 2015-06-19 Compugen Ltd. Polipeptidi i polinukleotidi, te njihova uporaba kao ciljnih molekula za proizvodnju lijekova i bioloških sredstava
ES2836128T3 (es) 2008-04-16 2021-06-24 Univ Johns Hopkins Método para determinar variantes del receptor de andrógenos en cáncer de próstata
EP2483304B1 (de) 2009-09-29 2016-05-04 F.Hoffmann-La Roche Ag Vorfiltrationseinstellung von gelösten pufferstoffen zur herstellung einer hochkonzentrierten immunglobulinzubereitung
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2322149A1 (de) 2009-11-03 2011-05-18 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Ischämie
EP2338492A1 (de) 2009-12-24 2011-06-29 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Alzheimer
WO2011103389A1 (en) 2010-02-19 2011-08-25 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
SMT201900219T1 (it) 2010-06-14 2019-05-10 Lykera Biomed S A Anticorpi anti-s100a4 e relativi usi terapeutici
CA2805653A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
ES2997080T3 (en) 2010-10-25 2025-02-14 Biogen Ma Inc Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
CA2817418A1 (en) 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
ES2847304T3 (es) 2011-01-17 2021-08-02 Lykera Biomed S A Anticuerpos contra la proteína S100P para el tratamiento y diagnóstico de cáncer
WO2012100835A1 (en) 2011-01-28 2012-08-02 Laboratorios Del Dr. Esteve, S.A. Methods and compositions for the treatment of aids
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
WO2012170071A1 (en) 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
AU2012315474B2 (en) 2011-09-30 2017-10-26 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against TL1a and uses thereof
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
US9617336B2 (en) 2012-02-01 2017-04-11 Compugen Ltd C10RF32 antibodies, and uses thereof for treatment of cancer
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
CA2899960C (en) 2013-02-01 2022-05-03 Transbio Ltd Anti-cd83 antibodies and use thereof
FI2953971T3 (fi) 2013-02-07 2023-04-27 Csl Ltd Il-11r-sitojaproteiineja ja niiden käyttöjä
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
PT2984108T (pt) 2013-04-09 2017-09-19 Lykera Biomed S A Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP2876114A1 (de) 2013-11-25 2015-05-27 Consejo Superior De Investigaciones Científicas Antikörper gegen CCR9 und Anwendungen davon
EP3530286A1 (de) 2013-11-28 2019-08-28 CSL Limited Verfahren zur behandlung von diabetischer nephropathie
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
CA2932465C (en) 2013-12-18 2023-08-22 Csl Limited Methods of treating wounds in a diabetic subject
EP3119910A4 (de) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 und resistenzassoziierte mutationen
WO2015179404A1 (en) 2014-05-19 2015-11-26 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
JP2017523207A (ja) * 2014-08-08 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用
US11345956B2 (en) 2014-08-25 2022-05-31 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
WO2016061617A1 (en) 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
KR102802396B1 (ko) 2015-11-27 2025-05-07 씨에스엘 리미티드 Cd131 결합 단백질 및 이의 용도
CN105628935A (zh) * 2016-03-01 2016-06-01 广东医学院附属医院 一种检测人尿中cd80的试剂盒
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
AU2017331739A1 (en) 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof
KR101926834B1 (ko) 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
CA3058290A1 (en) 2017-04-18 2018-10-25 Universite Libre De Bruxelles Biomarkers and targets for proliferative diseases
EP4512469A3 (de) 2017-09-11 2025-05-21 Monash University Bindung von proteinen an den menschlichen thrombinrezeptor par4
AU2018350370B2 (en) 2017-10-18 2023-05-04 Csl Limited Human serum albumin variants and uses thereof
EP3768701B1 (de) 2018-03-23 2023-08-02 Université Libre de Bruxelles Agonistenmoleküle des wnt-signalwegs
SG11202010596PA (en) 2018-05-16 2020-11-27 Csl Ltd Soluble complement receptor type 1 variants and uses thereof
US12139537B2 (en) 2018-06-22 2024-11-12 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
US12234289B2 (en) 2018-12-07 2025-02-25 Ono Pharmaceutical Co., Ltd. Immunosuppresive agent
JP7807372B2 (ja) 2019-12-20 2026-01-27 ハドソン インスティチュート オブ メディカル リサーチ Ｃｘｃｌ１０結合タンパク質及びその使用
WO2022013613A2 (en) 2020-07-17 2022-01-20 Onena Medicines S.L. Antibodies against lefty proteins
WO2023089131A1 (en) 2021-11-19 2023-05-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025171411A1 (en) 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
EP4703381A1 (de) 2024-09-03 2026-03-04 Institució Catalana de Recerca i Estudis Avançats Antikörper gegen icam-1 und anwendungen davon

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4777245A (en) * 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5045469A (en) * 1988-10-27 1991-09-03 Mycogen Corporation Novel bacillus thuringiensis isolate denoted B. T. PS81F, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5304635A (en) * 1990-03-12 1994-04-19 University Of Southern California Antigen specifically expressed on the surface of B cells and Hodgkin's cells
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
BR9206313A (pt) 1991-07-25 1995-04-11 Idec Pharma Corp Anticorpos recombinantes para terapia humana.
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
WO1994028912A1 (en) 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression
WO1995006481A1 (en) 1993-09-02 1995-03-09 Trustees Of Dartmouth College Methods for inducing antigen-specific t cell tolerance
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
EP1878748A2 (de) 1996-11-08 2008-01-16 Biogen Idec Inc. Identifikation der Wechselwirkungen einzelner Bindungen zwischen gewissen Antikörpern und humanen kostimulierenden B7.1- und B7.2-Antigenen
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40

Also Published As

Publication number Publication date
EP0837927B1 (de) 2008-01-16
AU6331296A (en) 1996-12-30
US6709654B1 (en) 2004-03-23
JP4242451B2 (ja) 2009-03-25
NO975598L (no) 1998-02-09
KR100496307B1 (ko) 2005-11-25
US20010024648A1 (en) 2001-09-27
US20050129688A1 (en) 2005-06-16
UY24256A1 (es) 1996-06-18
AR001288A1 (es) 1997-10-08
HK1015413A1 (en) 1999-10-15
EP0837927A1 (de) 1998-04-29
DK0837927T3 (da) 2008-05-13
NO975598D0 (no) 1997-12-03
BR9609035A (pt) 1999-07-06
NZ311904A (en) 1999-09-29
IL122370A0 (en) 1998-06-15
CO4480111A1 (es) 1997-07-09
ES2301169T3 (es) 2008-06-16
CN100379855C (zh) 2008-04-09
AU707023B2 (en) 1999-07-01
CN101367877A (zh) 2009-02-18
EP0837927A4 (de) 2000-01-05
NO328554B1 (no) 2010-03-22
YU35996A (sh) 1998-12-23
KR19990022650A (ko) 1999-03-25
DE69637408D1 (de) 2008-03-06
ZA964547B (en) 1997-01-24
US6113898A (en) 2000-09-05
US6893638B2 (en) 2005-05-17
US7323170B2 (en) 2008-01-29
CA2223532A1 (en) 1996-12-19
IL122370A (en) 2000-07-26
EP1914301A1 (de) 2008-04-23
PT837927E (pt) 2008-04-28
CA2223532C (en) 2010-11-09
DE69637408T2 (de) 2009-01-15
MY136224A (en) 2008-08-29
AR053814A2 (es) 2007-05-23
JPH11508764A (ja) 1999-08-03
WO1996040878A1 (en) 1996-12-19
CN1192779A (zh) 1998-09-09
SA96170473B1 (ar) 2005-07-31

Similar Documents

Publication Publication Date Title
ATE384125T1 (de) Antikörper gegen cd-80
DK0865562T3 (da) Rørledningsforbindelsesdel
DE69617896D1 (de) Humaner monoklonaler Antikörper gegen VEGF
ATE267257T1 (de) Humanisierte anti-koerper gegen cd11a
DE69614611D1 (de) Rohrverbindung
DE59610558D1 (de) Stativ
DE69621292D1 (de) Rohrverbindung
DE69634279D1 (de) Verbinder
FI973028L (fi) Muoviputki
DE69602671D1 (de) Verbinder
DE69614207D1 (de) Rohrverbindung
DE69509061D1 (de) Drosselklappe
DE69621557D1 (de) Kopiergerät
DE69622977D1 (de) Drosselklappe
DE59606218D1 (de) Rohrleitung
DE59606840D1 (de) Rohrverbindung
DE69624334D1 (de) Fixiervorrichtung
DE69610536D1 (de) Rohrverbindung
DE69611468D1 (de) Elektrophotographisches Gerät
DE69621746D1 (de) Verbinder
DE69631941D1 (de) Elektrophotographisches Gerät
DE69603897D1 (de) Verbinder
DE69600824D1 (de) Rohrverbindung
KR960037970U (ko) 절첩식 파이프
KR960035141U (ko) 파이프 분배기

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0837927

Country of ref document: EP